NGF stimulation of erk phosphorylation is impaired by a point mutation in the transmembrane domain of trkA receptor

Journal of Molecular Neuroscience

Volumn 14, Issue 1-2, 2000, Pages 69-76

  Monshipouri, Mariam ^a   Jiang, Hao ^b   Lazarovici, Philip ^c  

^a US Department of Commerce   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Erk; Impairment; Mutation; NGF; Recombinant receptor; Transmembrane domain; TrkA; Tyrosine kinase

Indexed keywords

NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; HORMONE ACTION; HORMONE BINDING; HORMONE RECEPTOR INTERACTION; NONHUMAN; POINT MUTATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0034039955     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:14:1-2:069     Document Type: Article

References (31)

1. Baranski T. J., Herzmark P., Lichtarge O., Gerber B. O., Trueheart J., Meng E. C., et al. (1999) C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J. Biol. Chem. 274, 15,757-15,765.
2. Bonaventure J., Rousseau F., Legeai-Mallet L., LeMerrer M., Munnich A., and Maroteaux P. (1996) Common mutations in the fibroblast growth factor receptor 3 (FGFR3) gene account for achondroplasia, hypochondroplasia and thanatophoric dwarfism. Am. J. Med. Genet. 63, 148-154.
3. Briggs C. A., McKenna D. G., Monteggia L. M., Touma E., Roch J. M., Arneric S. P., et al. (1999) Gain of function mutation of the alpha 7 nicotinic receptor: distinct pharmacology of the human alpha 7V274T variant. Eur. J. Pharmacol. 366, 301-308.
4. Carpenter C. D., Ingrahm H. A., Cochet C., Walton G. M., Lazar C. S., Sowadski J. M., et al. (1991) Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J. Biol. Chem. 266, 5750-5755.
5. Clarke W. P. and Bond R. A. (1998) The elusive nature of intrinsic activity. Trends Pharmacol. Sci. 19, 270-276.
6. + channel openers. Mol. Pharmacol. 56, 308-315.
7. Frattali A. L., Treadway J. L., and Pessin J. E. (1991) Evidence supporting a passive role of the insulin receptor transmembrane domain in insulin-dependent signal transduction. J. Biol. Chem. 266, 9829-9834.
8. Greene L. A. and Kaplan D. R. (1995) Early events in neurotrophin signaling via trk and p75 receptors. Curr. Opin. Neurobiol. 5, 579-587.
9. Guy P. M., Carraway K. L., and Cerione R. A. (1992) Biochemical comparison of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases. J. Biol. Chem. 267, 13,851-13,856.
10. Hoffman C., Moro S., Nicholas R. A., Harden T. K., and Jacobson K. A. (1999) The role of amino acids in extracellular loops of the human P241 receptor in surface expression and activation processes. J. Biol. Chem. 274, 14,639-14,647.
11. Jiang H., Shah S., and Hilt D. C. (1993) Characterization, sequence and expression of murine S100 beta gene. J. Biol. Chem. 268, 20,502-20,511.
12. trk-deficient, PC12/endothelial cells results in nerve growth factor-induced transduction and DNA synthesis. J. Cell Biochem. 66, 229-244.
13. NGFR nerve growth factor receptors mediate nerve growth factor-stimulated calcium uptake. J. Biol. Chem. 272, 6835-6837.
14. Kaplan D. R., Hempstead B. L., Martin Z. D., Chao M. V., and Parada L. F. (1991) The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 252, 554-558.
15. Kaplan D. R. and Stephens R. M. (1994) Neurotrophin signal transduction by the trk receptor. J. Neurobiol. 25, 1404-1417.
16. Karplus P. A. and Schulz G. E. (1985) Prediction of chain flexibility in proteins. Naturwissenschaften 72, 212,213.
17. Kashles O., Szapary D., Bellot E, Ullrich A., Schlessinger J., and Schmidt A. (1988) Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane region. Proc. Natl. Acad. Sci. USA 85, 9567-9571.
18. Li Y., Mangasarian K., Mansukhani A., and Basilico C. (1997) Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 14, 1397-1406.
19. Lin Z., Wang W., Kopajtic T., Revay R. S., and Uhl G. R. (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56, 434-447.
20. Mardy S., Miura Y, Endo F., Matsuda I., Sztriha L., Frossard P., et al. (1999) Congenital insensitivity to pain with anhydrosis: novel mutations in the trkA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. Am. J. Human Genet. 64, 1570-1579.
21. Martin-Zanca D., Barbacid M., and Parada L. F. (1990) Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev. 4, 683-694.
22. Martin-Zanca D., Hughes S. H., and Barbacid M. (1986) A human oncogene formed by the fusion of truncated tropamyosin and protein tyrosine kinase sequence. Nature 319, 743-748.
23. McNeil A., Larkins R., and Clark S. (1996) The uncoupling of SHC activation from distal intracellular signalling in a cell line which expresses a truncated human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 218, 740-744.
24. Miloso M., Mazzotti M., Vass W. C., and Bequinot L. (1995) SHC and GRB2 are constitutively by an epidermal growth factor receptor with a point mutation in the transmembrane domain. J. Biol. Chem. 270, 19,557-19,562.
25. Scheer A., Fanelli F., Diviani D., Benedetti P. G., and Cotecchia S. (1999) Structure-function relationships of the alpha 1b-adrenergic receptor. Eur. Urol. 36 (Suppl. 1), 11-16.
26. Takahashi K., Yonezawa K., and Nishimoto I. (1995) Insulin-like growth factor I receptor activated by a transmembrane mutation. J. Biol. Chem. 270, 19,041-19,045.
27. Thoenen H. and Barde Y. A. (1980) Physiology of nerve growth factor. Physiol. Rev. 60, 1284-1335.
28. Thompson S. A., Arden S. A., Marshall G., Wingrove P., Whiting P. J., and Wafford K. A. (1999) Residues in transmembrane domains I and II determine γ-aminobutyric acid type A receptor subtype-selective antagonism by furosemide. Mol. Pharmacol. 55, 993-999.
29. + channels derived from point mutations in the transmembrane segment D4-S6. Biophys. J. 76, 3141-3149.
30. Watson F. L., Porcionatto M. A., Bhattacharyya A., Stiles C. D., and Segal R. A. (1999) TrkA glycosylation regulates receptor localization and activity. J. Neurobiol. 39, 323-326.
31. Wess J., Blin, N., Mutschler E., and Blumi K. (1995) Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci. 56, 915-922.